Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul;211(7):1124-1126.
doi: 10.1164/rccm.202504-0944ED.

From Blood to Vessel: Lipid Ratios in Pulmonary Hypertension

Lars Harbaum  1   2   3 , Hans Klose  1 , Martin R Wilkins  2   3
Affiliations
Editorial

From Blood to Vessel: Lipid Ratios in Pulmonary Hypertension

Lars Harbaum et al. Am J Respir Crit Care Med. 2025 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Bordag and colleagues investigated the diagnostic potential of lipid ratios in patients with different forms of pulmonary hypertension compared with healthy and diseased controls. They identified high diagnostic accuracy for ratios of free fatty acids to complex lipids and demonstrated direct effects of free fatty acids on pulmonary vascular cells. Figure includes elements from Servier Medical Art, licensed under CC BY 4.0. FFA = free fatty acid; IPAH = idiopathic pulmonary arterial hypertension; PH = pulmonary hypertension; SMC = smooth muscle cell.
See this image and copyright information in PMC

Comment on

  • Lipid Ratios for Diagnosis and Prognosis of Pulmonary Hypertension.
    Bordag N, Nagy BM, Zügner E, Ludwig H, Foris V, Nagaraj C, Biasin V, Kovacs G, Kneidinger N, Bodenhofer U, Magnes C, Maron BA, Ulrich S, Lange TJ, Eichmann TO, Hoetzenecker K, Pieber T, Olschewski H, Olschewski A. Bordag N, et al. Am J Respir Crit Care Med. 2025 Jul;211(7):1264-1276. doi: 10.1164/rccm.202407-1345OC. Am J Respir Crit Care Med. 2025. PMID: 40343938 Free PMC article.

References

    1. Hemnes A, Rothman AMK, Swift AJ, Zisman LS. Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension. Pulm Circ . 2020;10:2045894020957234. - PMC - PubMed
    1. Harbaum L, Rhodes CJ, Otero-Núñez P, Wharton J, Wilkins MR. The application of ‘omics’ to pulmonary arterial hypertension. Br J Pharmacol . 2021;178:108–120. - PubMed
    1. Lee MH, Sanders L, Kumar R, Hernandez-Saavedra D, Yun X, Ford JA. et al. Contribution of fatty acid oxidation to the pathogenesis of pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol . 2022;323:L355–L371. - PMC - PubMed
    1. Legchenko E, Chouvarine P, Borchert P, Fernandez-Gonzalez A, Snay E, Meier M. et al. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med . 2018;10:eaao0303. - PubMed
    1. Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Lopaschuk GD. et al. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med . 2010;2:44ra58. - PubMed

LinkOut - more resources